Evaluation of VEDAN RT-90 Resistant Cassava Starch for Glycemic Control and Prebiotic Fiber Development in a Human Trial

This study aims to investigate the effects of RT-90 resistant cassava starch on glycemic control using a human dietary trial and to evaluate its potential as a prebiotic fiber supplement. This study will assess the efficacy of RT-90 resistant cassava starch in improving glycemic control, body composition, and gut microbiome in healthy individuals.

Study Overview

• Status: Not yet recruiting
• Conditions: Blood Sugar; Resistant Starch; Tapioca Starch; Prebiotic Fiber
• Intervention / Treatment: Dietary supplement: RT-90 resistant tapioca starch; Dietary supplement: control group; Dietary supplement: Commercially available resistant starch

Detailed Description

This study consisted of two phases.

The first phase was conducted in a randomized, cross-controlled manner. Before entering the study, participants maintained a normal diet and lifestyle for three consecutive days. Afterward, they entered the study and underwent a resistant starch assessment until the end of the study. Forty participants were randomly divided into two groups: 20 in each of the Weidan resistant starch group and the glucose powder group. Weidan resistant starch consists of tapioca resistant starch and glucose powder. Both groups consumed the sample within 5 minutes and then underwent an oral glucose tolerance test (OGTT). The participants fasted for 8-12 hours the day before the test (water was permitted). Blood samples (1 mL each) were collected at 0, 30, 60, 90, 120, and 180 minutes to monitor blood glucose levels. After the study, the two groups consumed either Weidan resistant starch or 50 g of glucose powder, each containing 50 g of total carbohydrates (57 g total product weight), dissolved in 250 mL of water, within 5 minutes, at least one week after the study. Blood glucose levels were monitored. After the study, the two groups alternated and consumed Weidan resistant starch or glucose powder again, followed by an oral glucose tolerance test and body composition measurements using the Inbody270 body composition analyzer.

The second phase of the study was conducted in a randomized, double-blind, placebo-controlled manner. Prior to entering the study, participants maintained a normal diet and lifestyle for three consecutive days. Afterward, they entered the study and underwent resistant starch assessment until completion. 75 subjects were randomly divided into three groups: the Weidan resistant starch group, the commercial resistant starch group, and the placebo control group. The ingredients of Weidan resistant starch are cassava resistant starch; the ingredients of commercial resistant starch are wheat resistant starch; and the placebo control group are natural cassava starch. The dosage is calculated based on 0.5 grams per kilogram of adult body weight (for example, a 60-kilogram adult needs to take 30 grams). The subjects were required to dissolve the test product in water and drink it on an empty stomach before their first meal each day for 12 weeks. The evaluation items at each follow-up visit included: (1) general physical examination (mental state, sleep, appetite, gastrointestinal symptoms, blood pressure, pulse and respiratory rate), (2) body measurement and body composition analysis (weight, BMI, waist circumference, hip circumference, subcutaneous fat thickness, skeletal muscle weight, body fat percentage and total water weight), (3) routine blood and biochemical examination, including red blood cell and white blood cell count, hemoglobin, hematocrit, mean corpuscular volume and platelets, renal function (urea nitrogen, creatinine, uric acid), thyroid hormone, liver function (AST, ALT, γ-GT and albumin), blood lipids (triglycerides, total cholesterol, free fatty acids, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol), electrolyte balance (sodium, potassium, chloride, phosphorus, calcium) and fasting blood glucose (blood volume was 15 mL, must fast for at least 8 hours), (4) diet and activity records (including 24-hour diet review and weekly gastrointestinal function symptom records), (5) analysis of intestinal related indicators, including short-chain fatty acids (SCFA) and intestinal flora (NGS). Samples were collected and analyzed at week 0 and week 12.

• Study Type: Interventional
• Enrollment (Estimated): 115
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Chin-Lin Professor; Phone Number: 04-24730022 Ext. 12222; Email: clhsu@csmu.edu.tw

Study Locations

• Taiwan
  • South
    • Taichung, South, Taiwan, 402 Recruiting
      • Chung Shan Medical University
      • Contact: Chin-Lin Hsu Professor; Phone Number: 04-24730022 Ext. 12222; Email: clhsu@csmu.edu.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Subjects aged 18-65 years.
• Healthy subjects (BMI between 18.5-24.9 kg/m² for women and men).
• Subjects must be able to maintain a stable diet (based on the Ministry of Health and Welfare's daily dietary guidelines, with a tolerance of ± 10-15%) and physical activity (based on the World Health Organization's recommendations of 150-300 minutes of moderate-intensity exercise per week, or equivalent physical activity, with a tolerance of ± 20%) during the trial period.
• Subjects must understand the trial procedures and potential risks and benefits described in the consent form and be able to sign the consent form.

Exclusion Criteria:

• Pregnant or breastfeeding women.
• Subjects with endocrine abnormalities, major organ disease, or mental illness (as determined by a physician).
• Subjects found to be intolerant to the test sample during the trial.
• Subjects who develop a disease or take medications or health supplements that could affect the results of the trial during the trial period. (e.g., hypoglycemic (lipid)-lowering medications, probiotics, high-dose dietary fiber supplements, fish oil, or supplements high in polyunsaturated fatty acids).
• Chronic gastrointestinal diseases (e.g., diverticular disease, irritable bowel syndrome, or other intestinal diseases that may cause constipation).
• Use of antibiotics within the past three months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: RT-90 resistant tapioca starch; Phase 1： Equivalent to 50 g total carbohydrates (57 g total product weight) of resistant starch dissolved in 250 mL of water Phase 2： The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Subjects should dissolve the test product in water and drink it on an empty stomach before their first meal of the day.	Dietary supplement: RT-90 resistant tapioca starch; Within 5 minutes, consume resistant starch containing 50 g of total carbohydrates (total product weight 57 g), dissolved in 250 mL of water, and perform an oral glucose tolerance test to monitor blood sugar changes. After the test, the two groups will switch and consume resistant starch or glucose powder again after at least 1 week.
Placebo Comparator: control group; Phase 1：50g glucose powder, dissolved in 250 mL of water Phase 2：The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Participants should dissolve the test product in water and drink it on an empty stomach before their first meal each day, continuing for 12 weeks.	Dietary supplement: control group; The subjects were asked to take a 50 g glucose powder dissolved in 250 mL of water within 5 minutes to conduct an oral glucose tolerance test to monitor blood sugar changes. After the test, the subjects were asked to empty their stomachs at least 1 week after the test and then switch to take RT-90 resistant starch or glucose powder again.
Active Comparator: Commercially available resistant starch; The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Subjects should dissolve the test product in water and drink it on an empty stomach before their first meal of the day.	Dietary supplement: Commercially available resistant starch; The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Participants should dissolve the test product in water and drink it on an empty stomach before their first meal each day, continuing for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1 Trial Changes in Fasting Blood Glucose from Baseline to End of Trial (Glycemic Index Test Phase)	Fasting blood glucose levels were measured at baseline and at the completion of the glycemic index (GI) test phase to assess short-term glycemic response. Blood Volume: 1 cc/times	Week 0 and 2
Phase 2 Changes from Baseline to End of Trial (Prebiotic Assessment)	Fasting blood glucose levels will be measured at baseline and 12 weeks after prebiotic supplementation to assess long-term metabolic response. Blood Draw Volume: 15 mL/dose	Week 0 to12
Phase 2 Changes from Baseline to End of Trial (Prebiotic Assessment	Ftool samples will be collected at Week 0 and Week 12 to analyze gut microbiota diversity.	Week 0 and Week 12

Collaborators and Investigators

• Sponsor: Chung Shan Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): December 20, 2025
• Primary Completion (Estimated): August 31, 2026
• Study Completion (Estimated): October 31, 2026

Study Registration Dates

• First Submitted: November 21, 2025
• First Submitted That Met QC Criteria: December 1, 2025
• First Posted (Actual): December 15, 2025

Study Record Updates

• Last Update Posted (Actual): December 15, 2025
• Last Update Submitted That Met QC Criteria: December 1, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Investigative Techniques; Epidemiologic Research Design; Epidemiologic Methods; Research Design; Methods; Control Groups
• Other Study ID Numbers: CS2-25120

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No